Scientific Scope

Our translational research group focuses on the molecular characterization of aggressive B-cell lymphomas, including the most common form of lymph node cancer, Diffuse Large B-cell Lymphoma (DLBCL), and other Large B-cell Lymphomas (LBCLs) such as Primary Central Nervous System Lymphoma (PCNSL), Primary Testicular Lymphoma (PTL), Primary Mediastinal Large B-cell Lymphoma (PBML) and Classical Hodgkin Lymphoma (cHL). 

Using genome-wide tools, such as applied (epi)genomics and integrated multi-omics in primary tissue and functional screens in informative model systems, we dissect molecular heterogeneity to identify actionable alterations and exploit novel cancer cell dependencies with the eventual goal to personalize treatment for lymphoma patients. Specifically, through integrative and comparative genomics, we identify unique genetic signatures and associated survival pathways for discrete LBCL subtypes, which are then modeled in vitro and in vivo to develop rational targets, novel biomarkers and novel clinical avenues in form of clincal trials.

Please find more details here: https://go.umg.eu/ag-chapuy

 

Most important Awards, Grants or Scientific Achievements

• Speaker, Aggressive Lymphoma Working Group, GLA
• Member, Program Committee Aggressive Lymphoma, German Society of Hematology and Oncology (DGHO)
• Managing Board and Member of the SFB1530
• Oncology Award, Gilead Sciences
• Medical Oncology Translational Award, Dana-Farber Cancer Institute/Harvard Medical School
• Claudia Adams Barr Award for Basic Cancer Research
• American Society of Hematology Achievement Award 2012-2015 (each year)

Selected References

• Chapuy, B.*, Stewart, C.*, Dunford, A.J.*, Kim, J., Wienand, K., Kamburov, A., Griffin, G.K., Chen, P.H., Lako, A., Redd, R.A., Cote, C.M., Ducar, M.D., Thorner, A.R., Rodig, S.J., Getz, G., Shipp, M.A. (2019) "Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade." Blood. 2019 Dec 26;134(26):2369-2382. PMID: 31697821
• Chapuy, B.*, Stewart, C.*, Dunford, A.*, Kim, J., Kamburov, A., Redd, R., Lawrence, M., Roemer, M.G.M., Li, A.J., Ziepert, M., Wala, J., Ducar, M.D., Leshchiner, I., Rheinbay, E., Taylor-Weiner, A., Coughlin, C., Hess, J., Pedamallu, C., Livitz, D., Rosenbrock, D., Rosenberg, M., Tracy, A., Horn, H., van Hummelen, P., Feldman, A.L., Link, B.K., Novak, A.J., Cerhan, J.R., Habermann, T.M., Siebert, R., Rosenwald, A.,Thorner, A.R., Meyerson, M., Golub, T.R., Beroukhim, R., Wulf, G.G., Ott, G., Rodig, S.J., Monti, S., Neuberg, D., Loeffler, M., Pfreundschuh, M., Trümper, L., Getz, G.*, Shipp, M.A.*(2018) "Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes." Nat Med. 2018 May;24(5):679-690.
• Chapuy, B.*, Roemer, M.G.M.*, Stewart, C., Tan, Y., Abo, R.P., Zhang, L., Dunford, A.J., Meredith, D.M., Thorner, A.R., Jordanova, E.S., Liu, G., Feuerhake, F., Ducar, M.D., Illerhaus, G., Gusenleitner, D., Linden, E., Sun, H.H., Homer, H., Aono, M., Pinkus, G.S., Ligon, A.H., Ligon, K., Ferry, J.A., Freeman, G., van Hummelen, P., Golub, T.R., Getz, G., Rodig, S.J., de Jong, D., Monti, S., Shipp, M.A.(2016) "Targetable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas." Blood. 2016 Feb 18;127(7):869-81.
• Chapuy, B.*, McKeown, M.R.*, Lin, C.Y., Monti, S., Roemer, M.G., Qi, J., Rahl, P.B., Sun, H., Yeda, K.T., Doench, J.G., Reichert, E., Kung, A.L., Rodig, S.J., Young, R.A., Shipp, M.A., Bradner, J.E.(2013) "Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma."Cancer Cell. 2013 Dec 9;24(6):777-90.
• Monti, S.*, Chapuy, B.*, Takeyama, K., Rodig, S.J., Hao, Y., Yeda, K.T., Inguilizian, H., Mermel, C., Curie, T., Dogan, A., Kutok, J.L., Beroukim, R., Neuberg, D., Habermann, T., Getz, G., Kung, A.L., Golub, T.R., Shipp, M.A.(2012) "Integrative Analysis Reveals an Outcome-associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B-cell Lymphoma. Cancer Cell. 2012 Sep 11;22(3):359-72.